Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan J Hollick

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Seminars in Cancer Biology|March 9, 2010
The discovery of nongenotoxic activators of p53: building on a cell-based high-throughput screenAnna R McCarthy, Jonathan J Hollick, Nicholas J Westwood
International Journal of Cancer|February 25, 2005
Pilot screening programme for small molecule activators of p53Rachel G Berkson, Jonathan J Hollick, Nicholas J Westwood, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK)Jonathan J Hollick, Bernard T Golding, Ian R Hardcastle, et al.
Bioorganic & Medicinal Chemistry|February 7, 2012
Synthesis and biological characterisation of sirtuin inhibitors based on the tenovinsAnna R McCarthy, Lisa Pirrie, Jonathan J Hollick, et al.
Cell Cycle (Georgetown, Tex.)|October 31, 2008
Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screenOliver D Staples, Jonathan J Hollick, Johanna Campbell, et al.
Cancer Cell|May 6, 2008
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activatorSonia Lain, Jonathan J Hollick, Johanna Campbell, et al.
Journal of Medicinal Chemistry|March 21, 2007
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinaseJonathan J Hollick, Laurent J M Rigoreau, Celine Cano-Soumillac, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Seminars in Cancer Biology|March 9, 2010
The discovery of nongenotoxic activators of p53: building on a cell-based high-throughput screenAnna R McCarthy, Jonathan J Hollick, Nicholas J Westwood
International Journal of Cancer|February 25, 2005
Pilot screening programme for small molecule activators of p53Rachel G Berkson, Jonathan J Hollick, Nicholas J Westwood, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK)Jonathan J Hollick, Bernard T Golding, Ian R Hardcastle, et al.
Bioorganic & Medicinal Chemistry|February 7, 2012
Synthesis and biological characterisation of sirtuin inhibitors based on the tenovinsAnna R McCarthy, Lisa Pirrie, Jonathan J Hollick, et al.
Cell Cycle (Georgetown, Tex.)|October 31, 2008
Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screenOliver D Staples, Jonathan J Hollick, Johanna Campbell, et al.
Cancer Cell|May 6, 2008
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activatorSonia Lain, Jonathan J Hollick, Johanna Campbell, et al.
Journal of Medicinal Chemistry|March 21, 2007
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinaseJonathan J Hollick, Laurent J M Rigoreau, Celine Cano-Soumillac, et al.
Pageof 1